Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘Metabolic Stress’

For the final postcard in our 2020 summer mini-series on the potential of immunometabolism in oncology R&D, we’re taking an in-depth look at the ways in which metabolic programming can overcome immunosuppression in the tumour microenvironment (TME), as well as looking at additional novel ways in which the fitness of T cells can be impacted.

We’ve already covered glutaminase, arginine, p38 and others, yet there are other metabolic effects to consider too, as we discover in our latest expert interview.  In the penultimate postcard, we looked at mitochondrial phenotypes and how they can impact both mitochondrial and T cell fitness, which are important aspects in making adoptive cell therapy (ACT) based approaches such as TILs and CAR-T cell therapies more effective.

Deep thoughts on immunometabolism and how it can impact antitumour response

These themes show up yet again, but in a rather different context because T cell fitness can also impact immune checkpoint blockade, oncogenic targeting, as well as transcriptional and epigenetic approaches.

As much as we have been slowing building up the evidence during this series, in the finale it’s now time to kick up things up a notch or two and draw some unifying ideas together.

We accomplish this feat with a rising young star in this particular niche, Dr Ping-Chih Ho, who is at the University of Lausanne.

He kindly spoke to BSB about his pioneering and prolific research, some of the critical questions he has sought to answer, plus what he sees are important future directions to consider in metabolism research.

To learn more from our oncology analysis and get a heads up on insights and commentary emerging on immunometabolism, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

It’s the dog days of summer in August, traditionally a time when many of us go on holiday and while that’s more challenging in the uncertain times of COVID-19, we at BSB are taking a break for the next three weeks as we recharge/renew for a busy autumn of virtual meetings.

We won’t be writing much about topical news or recent data for the next few weeks, but instead, while we’re taking time out we’ve prepared a six-part mini-series looking at immunometabolism and its potential for cancer immunotherapy.  We’ve run this kind of series every summer over the last couple of years and they’ve worked out rather well.

One of the things we did on Seasons 3 and 4 of the Novel Targets Podcast was to look at topics involving emerging areas of complex research, where we often didn’t know all the answers yet there were emerging data worthy of time and attention. Immunometabolism is certainly a topic which meets those criteria – it’s been on our list to do a deeper dive into for a while and here we are now, with some extended time to make the most of the opportunity to do it some justice.

We’re obviously dating ourselves in that we used to write letters or send postcards to friends and family from our holidays, this mini-series is very much in that style.

To be clear, this is not intended to be a comprehensive review of absolutely everything in the landscape, instead we’ll be reviewing some of the key concepts, showcasing important papers, and highlighting data at AACR20 that caught our attention. There will also be mention of a few emerging biotech companies in the field and for good measure we have three interviews with scientists at the forefront of research, which may have excellent translational potential to the clinic.

By the end of our three-week journey together, hopefully you’ll gain a greater understanding of the new product development potential for cancer immunometabolism and be better placed to put into context new data as it steadily emerges over the coming months.

In this first post, let’s set the scene by looking at immunometabolism and the role it plays in the fate, function, and fitness of T cells.

To learn more from our oncology analysis and get a heads up on insights and commentary on the emerging area of immunometabolism, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!